Beyond the batch: How digital twins are rewriting the rules of medicine
Amit Malviya, VP – QA, Zest Pharma, highlights how digital twins, AI and real-time release testing are reshaping pharmaceutical…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Category
Guest Blogs
Six business lessons from Cipla’s nine-decade journey
Author Vijay Martis explains how Cipla's business model, strategy and purpose shaped its growth over nine decades
USFDA and EUDRA dashboards offer lessons for strengthening India’s regulatory transparency
Milind Sathe analyses how public regulatory dashboards can support pharmaceutical innovation, compliance and patient safety in…
From fintech to aesthetic injectables: Lessons in navigating regulatory formalisation
Rishi Agrawal, CEO, TeamLease RegTech cautions that the recent CDSCO clarification on injectable cosmetic products signals a…
Why ingredient transparency matters more than ever in cosmeceuticals
Dr Aisshwarya Panddit highlights why ingredient transparency has become essential in modern cosmeceuticals amid rising consumer…
Beyond ozempic: GLP-1s and the next wave of anti-obesity drugs
Saloni Paliwal, Co-founder, Voy India highlights the evolution of GLP-1 therapies beyond Ozempic, examining the science, market…
India patent office can bridge the gap with global patent search platforms
The author highlights how India’s patent search ecosystem compares with WIPO, USPTO and Espacenet, and outlines the features…
How India reimagined healthcare in 12 years—and what comes next
Anil Matai, Director General, OPPI reflects on more than a decade of sweeping transformation under the leadership of Hon. Prime…
Pharmacy beyond pills: Why India needs better drug awareness and pharmacy practice
Dr Ashok Omray examines India’s growing culture of self-medication and highlights the urgent need for stronger pharmacy awareness…
An emerging disruption in drug traceability for India and beyond
Over the past two decades, I have worked closely on serialisation and traceability deployments in multiple markets, transitioning…
China+1 moment for pharma: How India can convert opportunity into long-term contracts
The global healthcare industry has long relied on China for the majority of its active ingredients, APIs, and chemicals, making…
Navigating legal and regulatory landscape of GLP-1 drugs in India
India is currently facing a growing public health issue, with recent data showing that nearly a quarter of the adult population is…
The cosmetic-medicine grey zone
Prof Dr Debraj Shome, Clinical Scientist and Research Mentor, QR678 opines that when molecules with known biological action are…
Tariffs & sustainability: Why Indian pharma can no longer treat them as separate conversations
For a long time, Indian pharmaceutical companies could treat trade policy as a background variable. The real focus in the last…
India’s counterfeit drug crisis and the role of AI
India is facing a perilous rise in counterfeit high-value medicines, from cancer immunotherapies like Keytruda (pembrolizumab) to…
Patent pause: Link extensions to pendency
India is now well-positioned to introduce a limited, risk-calibrated patent-term extension (PTE) mechanism tailored to Active…
An emerging disruption in drug traceability for India and beyond
Avi Chaudhuri, PhD, Founder, The Kulinda Consortium reviews the challenges of drug traceability and new approaches being developed…
Powering India’s biologics future: Industry-academia partnerships as the engine of growth
In just a decade, India’s bioeconomy has expanded from USD 10 billion in 2014 to over USD 165 billion in 2024, now contributing…
Next phase of growth: The case for innovation-led pharma organisations in India
Growth in India’s pharmaceutical industry is entering a more demanding phase, where existing methods are beginning to become less…
Phytopharmaceuticals in India: A case for perpetual ‘New Drug’-style regulation over ASU-style…
Introduction
Phytopharmaceuticals in India: Bridging Tradition, Science and “New Drug”-Style Regulation
Setting the stage…